BTK expression and its clinical significance in 32 cases of mantle cell lymphoma
10.3969/j.issn.1000-8179.2017.19.548
- VernacularTitle:32例套细胞淋巴瘤中BTK蛋白的表达及临床意义
- Author:
JIA XIAOHUI
1
;
KONG LINGZHE
;
WANG XIANHUO
;
ZHANG HUILAI
Author Information
1. 天津医科大学肿瘤医院淋巴瘤科
- Keywords:
Bruton tyrosine kinase;
mantle cell lymphoma;
progression-free survival;
ibrutinib
- From:
Chinese Journal of Clinical Oncology
2017;44(19):963-968
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To detect Bruton tyrosin kinase (BTK) expression in patients with mantle cell lymphoma (MCL) and analyze its correlation with clinical features and prognosis. Methods:A total of 32 cases of MCL tissues and 10 cases of benign lymph nodes were sampled and stained with immunohistochemical (IHC) staining. Clinical data of these patients were analyzed using SPSS 17.0. Results:BTK was positively expressed in MCL and normal lymphoid tissues and was more strongly expressed in MCL tissue than in normal lym-phoid tissue. Moreover, BTK expression level was correlated with Ki-67 and MIPI scores. Prognosis analysis showed that patients with high BTK expression exhibited shorter progression-free survival (PFS) than patients with low expression levels (P=0.030);however, no significant difference in overall survival (OS) was observed (P=0.073). Single-factor analysis of PFS showed that age≥65 years, ECOG score≥2, bone marrow involvement, strongly positive BTK expression, Ki-67>30%, and MIPI score≥6 are poor prognostic factors for patients with MCL. Only MIPI score≥6 is considered an independent poor prognostic factor in the multivariate analysis. Conclusion:BTK is strongly and positively expressed in patients with MCL, and its expression level is correlated with Ki-67 and MIPI scores. Patients with high-level BTK expression usually exhibit shorter PFS than those with low-level BTK expression;however, owing to short follow-up time and limited sample size, high-level BTK expression cannot be considered an independent poor prognostic factor for PFS.
